PVCT लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 01:29):
Our systems believe the stock currently is overvalued by -0.55% compare to its pairs and should correct downwards.

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...

Stats
आज की मात्रा	239 713
औसत मात्रा	199 596
बाजार मूल्य	53.28M
EPS	$-0.00120 ( Q1 \| 2024-05-14 )
अगली कमाई की तारीख	( $0 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.70 (Sector) 0 (Industry) 0
ATR14	$0.00300 (2.38%)

ACUT 16.78%

AIMD -3.89%

AKABY 0.00%

AOBI 0.00%

ARNI 417.24%

BETRF 0.00%

BRAXF 7.14%

BVNRY -7.81%

CLVLY -2.39%

COEP 1.05%

CPMV 0.00%

CRXM 0.00%

CSLLY 0.20%

ERGO 0.00%

GSTC 0.00%

IPCIF 0.00%

LVCLY 0.00%

MLCT 2.63%

NPTX 0.00%

NUGX 0.00%

OBMP -37.10%

OCEL -0.27%

ODTC 0.00%

OTLC 6.45%

PFND 0.00%

PROT 0.00%

PVCT 1.11%

QSAM -99.95%

RGBP 10.45%

RGBPP 0.00%

RSPI 8.11%

SIGY 0.00%

SILO 1.01%

SKYE 10.33%

SNNAQ 0.00%

SPHRY 0.00%

UCBJY 0.39%

USRM 0.00%

VGLS 100.00%

VICP 59.29%

WXXWY -1.02%

Insider Trading

Date	Person	Action	Amount	type
2024-06-20	Pershing Edward	Buy	0	8% Unsecured Convertible Promissory Note
2024-06-15	Pershing Edward	Buy	47 190	Series D-1 Convertible Preferred Stock
2024-06-15	Pershing Edward	Sell	0	8% Unsecured Convertible Promissory Note
2024-05-26	Pershing Edward	Buy	18 876	Series D-1 Convertible Preferred Stock
2024-05-26	Pershing Edward	Sell	0	8% Unsecured Convertible Promissory Note

INSIDER POWER
100.00
Last 100 transactions
Buy: 14 428 113 \| Sell: 0

सहसंबंध (AI algo v.1.1b): Overvalued: -0.55% $0.127 paired level. (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

Provectus सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Provectus वित्तीय

Annual	2023
राजस्व:	$557 710
सकल लाभ:	$548 789 (98.40 %)
EPS:	$-0.00740

FY	2023
राजस्व:	$557 710
सकल लाभ:	$548 789 (98.40 %)
EPS:	$-0.00740

FY	2022
राजस्व:	$989 042
सकल लाभ:	$925 264 (93.55 %)
EPS:	$-0.00850

FY	2021
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Provectus Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Provectus

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.